FDA Approves Intelerad’s InteleConnect® EV for Mobile Diagnostic Image Review

Published on:

Montreal, Canada – April 16, 2020 - Intelerad Medical Systems™, a leading global provider of medical imaging software and enterprise workflow solutions, today announced that the FDA has cleared its InteleConnect® EV solution for diagnostic image review on a range of mobile devices. Approval of Intelerad’s 510(k) submission comes at a critical time for healthcare systems and ensures that radiologists are able to collaborate and leverage resources in more creative ways, even when workstation access is not available.

Now, in addition to use on mobile devices for clinical purposes, InteleConnect EV is approved for mobile diagnostic image review as well. It can immediately be used on various iPad and iPhone models, with additional devices to follow. The FDA clearance comes as part of a recertification of the diagnostic functionality for Intelerad’s flagship product, IntelePACS®.

The ability to review images and collaborate with clinical staff through diagnostic radiology is key to ensuring the best possible patient outcomes, in any context. With mobile access to diagnostic quality images via InteleConnect EV, radiologists have the freedom to collaborate anytime, anywhere.

“For more than 20 years, Intelerad has provided innovative solutions that enable radiologists to deliver highly accurate diagnoses, at optimum productivity,” said Rick Rubin, Intelerad Founder & Chief Engineering Officer. “While a mobile device is not a replacement for a diagnostic workstation, this clearance offers powerful new flexibility for accessing diagnostic quality images with InteleConnect EV, even when radiologists are outside their standard work environments.”

In addition to InteleConnect EV for universal secure viewing, Intelerad TeleDiagnostics™ can be rapidly and securely deployed into existing infrastructures to support customers’ remote diagnostic and clinical collaboration workflow needs.
 

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.